0.05Open0.10Pre Close53 Volume188 Open Interest2.50Strike Price265.00Turnover125.33%IV52.69%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier30DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.1786Delta0.4310Gamma33.40Leverage Ratio-0.0026Theta0.0002Rho5.96Eff Leverage0.0013Vega
Werewolf Therapeutics Stock Discussion
Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
Werewolf Therapeutics (HOWL) presented interim Phase 1 clinical trial results for WTX-330, their tumor-activated IL-12 prodrug, at SITC's 39th Annual Meeting. The trial enrolled 25 patients with diverse solid tumors, showing favorable tolerability and encouraging efficacy. Key findings include a confirmed partial response in a ...
4 mins ago
Werewolf Therapeutics Announces Promising New Development Candidate, Wtx-921, a First-of-Its-Kind Il-10 Indukine™ Molecule for Inflammatory Diseases
📊⚡️📊
📊⚡️📊
No comment yet